Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug improves clinical outcomes in patients with late onset AD, joining a long list of unsuccessful attempts to treat AD with anti-amyloid therapies. DISCUSSION: These therapies are based on the assumption that Aβ accumulation is the primary pathogenic trigger of AD. Current evidence suggests that Aβ may actually accumulate as part of an adaptive response to long-term chronic brain stress stimuli that would make more suitable candidates for therapeutic intervention. SUMMARY: At this juncture it is no longer unreasonable to suggest that further iterations of anti-Aβ therapies should be halted. Clinicians and researchers should instead direct their attention toward greater understanding of the biological function of Aβ both in healthy and demented brains, as well as the involvement of long-term chronic exposure to stress in the etiology of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 3×
“; licensee BioMed Centra under the terms of the Creative Commons At unrestricted use, distribution, and reproductio Commons Public Domain Dedication waiver ( available in this article, unless otherwise stated clinically diagnosed with AD do not display Aβ accumulation-even though neurodegeneration is in progress [4,11…”
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“Secondly, there is no obvious rationale for following patients in whom Aβ plaques are already detectable, since the presence of those plaques occurs, according to the amyloid hypothesis itself, too late in the disease for treatment to be effective and does not necessarily correlate with neurodegeneration [3,12-18].”
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 1×
“In fact, in the largest genetic analyses of late-onset AD to date, the polymorphisms commonly observed are nearly all associated with cholesterol metabolism, endocytosis (an essential part of cholesterol processing), and inflammation [28-30] This evidence, together with imaging studies showing that Aβ accumulation can…”
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · cited 1×
“In that regard, several hypotheses that are not amyloid-centric have been proposed, although few have gained significant traction [6,31-35].”
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 2×
“At the same time, even the most recent bapineuzumab trial continues to be limited by edema formation, a symptom highly associated with cerebral amyloid angiopathy, the damaging vascular amyloid deposition that often co-occurs with AD [2,3,44].”
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 1×
“In fact, in the largest genetic analyses of late-onset AD to date, the polymorphisms commonly observed are nearly all associated with cholesterol metabolism, endocytosis (an essential part of cholesterol processing), and inflammation [28-30] This evidence, together with imaging studies showing that Aβ accumulation can…”
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 1×
“When the amyloid hypothesis was formed, strong evidence clearly supported that assumption: Not only do all familial cases of AD involve APP mutations that cause dysregulated Aβ production, cases of trisomy 21 (Down syndrome; DS) in which APP was overexpressed also exhibit Aβ plaque formation identical to that of AD pa…”
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
Cited by
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, E., & Trushina, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161088 · Cited by 1,750
PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease
Oksanen, M., Petersen, A. J., Naumenko, N., Puttonen, K., Lehtonen, Š., Gubert Olivé, M., Shakirzyanova, A., Leskelä, S., Sarajärvi, T., Viitanen, M., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.016 · Cited by 332
“Although considerable pre-clinical and clinical evidence supports the amyloid cascade model, all experimental therapies built on this hypothesis have thus far been unsuccessful in clinics (Castello et al., 2014; Golde et al., 2011).”
BackgroundTargeting neuroinflammation in Alzheimer’s disease
Bronzuoli, M. R., Iacomino, A., Steardo, L., & Scuderi, C. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s86958 · Cited by 255
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
Dionisio-Santos, D. A., Olschowka, J. A., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1453-0 · Cited by 184
“However, some have questioned whether targeting amyloid β production is sufficient to treat AD and if a revision of the amyloid hypothesis is needed [135, 136].”
Background
Metadata
- Authors
- Castello, M. A., Jeppson, J. D., & Soriano, S.
- Venue
- BMC Neurology
- Published
- 2014-09-02
- Volume
- 14
- Issue
- 1
- Pages
- 169-169
- ISSN
- 1471-2377 (ISSN-L)
- OpenAlex
- W2128839325
- Cited by
- 77
- References
- 20
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s12883-014-0169-0
- The paper
- Castello, M. A., Jeppson, J. D., & Soriano, S. (2014). Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease. BMC Neurology. https://doi.org/10.1186/s12883-014-0169-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.